Picture of Bioxyne logo

BXN Bioxyne Income Statement

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapFalling Star

Annual income statement for Bioxyne, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.

2017
June 30th
2018
June 30th
2019
June 30th
2020
June 30th
2021
June 30th
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue1.791.992.132.262.11
Cost of Revenue
Gross Profit0.980.9371.141.221.08
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses2.823.573.612.992.68
Operating Profit-1.03-1.58-1.47-0.727-0.572
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-0.766-1.31-1.27-0.593-0.496
Provision for Income Taxes
Net Income After Taxes-0.766-1.31-1.27-0.593-0.496
Net Income Before Extraordinary Items
Net Income-0.766-1.31-1.27-0.593-0.496
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-0.766-1.31-1.27-0.593-0.496
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.002-0.002-0.002-0.001-0

Or unlock with your email

Or unlock with your email